Should Type 2 Care Report Require Action From DexCom (DXCM) Investors?

• DexCom published its 2026 “State of Type 2” report and announced a CGM partnership with Team Novo Nordisk, highlighting strong user outcomes alongside ongoing challenges in awareness and reimbursement.
• The research indicates that GLP-1 and CGM are often paired for Type 2 patients already using injectables, while non insulin users remain a largely untapped group despite reported benefits.
• This article examines how DexCom’s Type 2 access data and the GLP-1 pairing opportunity influence the broader CGM investment narrative.

Scan for other glucose and cardiometabolic stocks that could benefit from similar treatment tailwinds with our curated 34 healthcare AI stocks aligned to this DexCom CGM and GLP-1 convergence story.

DexCom Investment Narrative Recap

For DexCom, the core belief is that continuous glucose monitoring keeps expanding beyond intensive insulin users into Type 2, prediabetes and broader metabolic health. The new State of Type 2 report underlines that problem and opportunity at the same time. Strong reported outcomes meet low awareness and reimbursement friction, so the operational story still hinges on converting covered lives into active users.

In the near term, the key swing factor is how quickly DexCom can turn GLP 1 pairing and Type 2 non insulin coverage into measurable volume, without sacrificing pricing. The biggest risk remains reimbursement pressure, especially potential CMS competitive bidding and country specific funding hurdles, which could squeeze margins just as the Ireland plant ramps.

The Type 2 report is the most relevant update here. It puts hard numbers around GLP 1 and CGM pairing, with 58% uptake among GLP 1 users versus 27% in Type 2 non insulin patients. That gap matters because management has been emphasizing non insulin and prediabetes adoption as a major way to build on the US$4.97b revenue base.

Evidence that users report better self management and treatment adherence supports the operational thesis but does not change the risk list. Pricing pressure from Medicare competitive bidding, manufacturing ramp costs in Ireland and rising competition in Type 1 all remain in the background. For investors, execution now is about translating this convergence story into sustainable sensor demand while maintaining margins.

What The DexCom Consensus Is Pricing In

DexCom's narrative projects US$6.8b revenue and US$1.5b earnings by 2029. This rests on analysts assuming 11.2% yearly revenue growth and an earnings increase of roughly US$500m from US$999.7m today.

Analysts linking GLP 1 pairing, Type 2 expansion and broader reimbursement to DexCom's investment story are also anchoring on a defined financial glide path. The consensus assumes revenue grows at 11.2% annually over the next three years, with profit margins moving from 20.1% today to 21.8% over that stretch. On the earnings line, the group view points to US$1.5b of profit and earnings per share of US$3.75 by 2029, compared with US$999.7m today.

That earnings move implies DexCom would add roughly half a billion dollars of profit on this timetable. To support current targets, analysts plug those 2029 earnings into a P/E of 26.9x, down from 33.7x today but still above the 24.8x level cited for the broader US medical equipment peer group. Forecasts also assume the share count declines by about 3.24% per year for the next three years, which supports earnings per share even if net income tracks the consensus line.

Putting the pieces together, the valuation sketch most often cited by brokers clusters around a US$94.48 price target. At a current share price of US$89.35, that target is only 5.4% higher, so the stock is treated as broadly fairly priced on these inputs rather than deeply discounted. For that US$94.48 to hold, the market would eventually need to see DexCom producing US$6.8b of sales and US$1.5b of earnings in 2029, alongside a P/E that compresses from current levels but still clears the industry average.

Uncover why DexCom's fair value indicates a 13% potential upside to its current price that may not last much longer.

Exploring Other Perspectives

One alternate view on DexCom focuses on slower Type 2 adoption rather than reimbursement wins. The most cautious analysts were modeling about US$6.6b of revenue and US$1.4b of earnings by 2029, paired with a lower 23.7x P/E. These forecasts came before the new Type 2 report, so opinions may shift. You can use this spread in expectations as a reminder that reasonable investors can read the same data very differently. This is why comparing several narratives before deciding how you feel about DexCom can really help.

Explore 2 other DexCom fair value estimates, including one that suggests it could be worth just $94.48.

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider relying on your own analysis.

• A great starting point for your DexCom research is our analysis highlighting 3 key rewards that could impact your investment decision.
• See our latest analysis for DexCom. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate DexCom's overall financial health at a glance.

Looking For More Investment Ideas Beyond DexCom?

Once you have a view on DexCom, it can help to widen the lens and compare it with other companies that fit different risk and return profiles. The Simply Wall St screener gives you a quick way to scan for stocks that line up with your own preferences around quality, value, income and balance sheet strength.

• If capital preservation matters most to you, start with a set of companies that score well on stability and balance sheet quality using the 31 resilient stocks with low risk scores.
• If you want to focus on quality at a reasonable price, compare DexCom with a curated 27 high quality undervalued stocks that pairs solid fundamentals with attractive valuations.
• If you prefer to hunt for earlier stage opportunities before they are widely followed, look through a 19 high quality undiscovered gems that screens for strong financial profiles with less market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com